These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1631 related items for PubMed ID: 18290748

  • 1. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 2. [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
    Manfredi R, Calza L.
    Recenti Prog Med; 2008 Oct; 99(10):492-501. PubMed ID: 19040127
    [Abstract] [Full Text] [Related]

  • 3. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM, BICOMBO Study Team.
    J Acquir Immune Defic Syndr; 2009 Jul 01; 51(3):290-7. PubMed ID: 19398921
    [Abstract] [Full Text] [Related]

  • 4. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.
    N Engl J Med; 2009 Dec 03; 361(23):2230-40. PubMed ID: 19952143
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.
    J Acquir Immune Defic Syndr; 2010 Sep 03; 55(1):49-57. PubMed ID: 20431394
    [Abstract] [Full Text] [Related]

  • 6. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T, Komatsu H, Teruya K, Tanuma J, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
    AIDS; 2013 Mar 13; 27(5):839-42. PubMed ID: 23719354
    [Abstract] [Full Text] [Related]

  • 7. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Jul 31; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.
    Antivir Ther; 2013 Jul 31; 18(6):745-54. PubMed ID: 23558061
    [Abstract] [Full Text] [Related]

  • 11. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM, BICOMBO Study Team.
    AIDS; 2010 Jan 28; 24(3):F1-9. PubMed ID: 20009917
    [Abstract] [Full Text] [Related]

  • 12. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb 28; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

  • 13. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
    Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, Brinson C, Benson P, Dau L, Wang H, White K, Flaherty J, Fralich T, Guyer B, Piontkowsky D.
    Clin Infect Dis; 2013 Jun 28; 56(11):1637-45. PubMed ID: 23362296
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M, Arumainayagam J, Kumari B, Ahmed-Jushuf I, Carlin EM, Chandramani S, Riddell L, Ghanem M, Das S.
    Int J Clin Pract; 2013 Sep 28; 67(9):922-3. PubMed ID: 23952469
    [No Abstract] [Full Text] [Related]

  • 15. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL, Deeks ED.
    Drugs; 2015 Apr 28; 75(5):503-14. PubMed ID: 25698454
    [Abstract] [Full Text] [Related]

  • 16. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H.
    AIDS Clin Care; 2008 Apr 28; 20(4):28. PubMed ID: 19271262
    [No Abstract] [Full Text] [Related]

  • 17. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D, Bicombo-met Substudy Team.
    Antivir Ther; 2011 Apr 28; 16(4):459-68. PubMed ID: 21685533
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA.
    J Antimicrob Chemother; 2008 Dec 28; 62(6):1365-73. PubMed ID: 18854330
    [Abstract] [Full Text] [Related]

  • 19. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group.
    Lancet; 2011 Jul 16; 378(9787):238-46. PubMed ID: 21763936
    [Abstract] [Full Text] [Related]

  • 20. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
    McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.
    J Infect Dis; 2013 Feb 15; 207(4):604-11. PubMed ID: 23204164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.